We are live on ! Find out more
PVCT

Provectus Biopharmaceuticals
PVCT

Delisted

PVCT was delisted on the 13th of October, 2016.

39 hedge funds and large institutions have $3.92M invested in Provectus Biopharmaceuticals in 2014 Q4 according to their latest regulatory filings, with 14 funds opening new positions, 5 increasing their positions, 5 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

310% more capital inflows, than outflows

Capital inflows: $1.23M | Capital outflows: $300K

250% more first-time investments, than exits

New positions opened: 14 | Existing positions closed: 4

30% more funds holding

Funds holding: 30 → 39 (+9)

0.39% more ownership

Funds ownership: 2.33% → 2.72% (+0.39%)

0% more repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 5

Holders
39
Holders Change
+9
Holders Change %
+30%
% of All Funds
1.04%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
14
Increased
5
Reduced
5
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

PVCT Hedge Fund Activity: Q4 2014 in Review

39 of the 3,765 institutional investors tracked by Wall St. Rank reported a position in Provectus Biopharmaceuticals (PVCT) for Q4 2014, worth a combined $3.92M — down 6.4% from $4.19M a quarter earlier.

Buyers outnumbered sellers: 14 funds opened new PVCT positions and 4 closed out — a net gain of 10 holders — while 5 added to existing stakes and 5 trimmed.

The largest buyer was Virtu KCG Holdings, adding an estimated $442K. The largest seller was Goldman Sachs, cutting an estimated $254K.

  • 39 institutional investors held Provectus Biopharmaceuticals (PVCT) as of Q4 2014, up from 30 in Q3 2014.
  • Funds reported $3.92M of Provectus Biopharmaceuticals stock for Q4 2014, down 6.4% quarter-over-quarter.
  • 14 funds opened new Provectus Biopharmaceuticals positions in Q4 2014 and 4 closed out, a net change of +10 holders.
  • The largest Provectus Biopharmaceuticals buyer in Q4 2014 was Virtu KCG Holdings, an estimated $442K added.
  • The largest Provectus Biopharmaceuticals seller in Q4 2014 was Goldman Sachs, an estimated $254K sold.

Based on aggregated 13F filings for Q4 2014.